People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lixte Biotechnology Holdings, Inc. | — | Biotechnology | Series A | $9.8M | $29.1M | 2023 |
Bas Van Der Baan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bas Van Der Baan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Weingarten | 1 | 3 |
| Stephen K. Carter | 1 | 2 |
| Mel Sorenson | 1 | 1 |
| Mel F. Sorenson | 1 | 1 |
| Yun Yen | 1 | 1 |
| James Miser | 1 | 1 |
| Regina Brown | 1 | 1 |
| John Kovach | 1 | 1 |
| Rene Bernards | 1 | 1 |
| Eric Forman | 1 | 1 |
| Stephen Forman | 1 | 1 |
| Winson (Sze Chun) Ho | 1 | 1 |
| John S. Kovach | 1 | 1 |
| Philip Palmedo | 1 | 1 |
| Philip F. Palmedo | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.